Pharma Industrial India

Dear Readers, Pharma Industrial India Magazine is happy to share its latest work i.e January-February 2025 issue with you. The issue brings standalone thought leadership from: Shoeb Kurawadwala, Founder and Managing Director, CN Water Systems; Bernhard Meir, Head of Continuous Manufacturing Activities, Gericke Group; Hartmut vom Bey, VP- Sales & Technology, Gerteis Maschinen + Processengineering AG; Bobby (Ananya) Abhishek Madaan, Director, Toshi Automation Solutions Limited; Rüdige (Rudi) Gall – General Manager / VP of Business Development, SC EMEA & Global Pharma, Germany; FALGUN JANI – Business Head, India, Freudenberg Medical; Chinmay Korad – Country Head, Pharma, Freudenberg Filtration Technologies India; Senthil Kumar, E – Sr. General Manager, Industrial Services Division, Freudenberg-NOK India The issue also offers insight into various sectors through thought pieces from various industry pioneers and accelerators: Manoj Kochar, President of ASPA ; Deepesh Upadhyay , Asst. Vice President, Delair India Pvt Ltd; Madhur Singhal, Managing Partner, Healthcare and Lifesciences; Ayush Singh, Practice Member, Healthcare and Lifesciences at Praxis Global Alliance; Vishal Goel, MD, Rx Propellant; Tiago Pires, Equipment & Facilities Division Manager, Telstar Portugal; Shlomo Sackstein, CEO Biopuremax Ltd.; Keren Zigelboim, BD, Biopuremax Ltd. Do read the Complete magazine here: https://lnkd.in/gNtizxNh We hope you enjoy our work!!! #biotech #india #healthcare #manufacturing #drugsanddevelopment #equipment #treatment #biotechnology #globalpharma #pharmaceuticals #PharmaIndustialIndia

A first in human proof of concept phase I clinical study of VAS-101 (Vasceptor®; topical curcumin gel) in sickle cell disease (SCD) is underway. The study is being conducted by the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Florida, under the supervision of the principal investigator, Dr. Gershwin Blyden. #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/dtdeBbbn

Norgine has entered into a #definitiveagreement to #acquire theravia, enhancing its rare disease portfolio with established treatments in rare #haematology and #hepatology. Janneke van der Kamp Franck Hamalian #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/dAVK8ZiD

Biocon Biologics has signed a settlement and #licenseagreement with Regeneron, paving the way to launch its interchangeable aflibercept biosimilar, YESAFILI, in the US by the second half of 2026. Shreehas Tambe #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/dRdkiVZ8

ActiveProtective® (APT) is proud to announce the launch of #Tango®Belt, a wearable #medicaldevice utilizing sensors to monitor motion and deploy airbags during serious hip-impacting falls. Wamis Singhatat #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/daWHeKWE

Celltrion Inc, Inc. has announced that the US Food and Drug Administration (FDA) has designated YUFLYMA® (adalimumab-aaty), as an interchangeable biosimilar to Humira® (adalimumab). Tom Nusbickel #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/dwAjv3ek

Sumitomo Pharma America, Inc. has announced that it has entered into a #CooperativeResearchandDevelopmentAgreement (CRADA) with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to evaluate enzomenib, an investigational, oral, small molecule designed to inhibit the menin and KMT2A protein interaction present in certain difficult to treat #cancers. Jatin S. #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/d5wPeDBq

CytoSorbents Corporation announced the #appointment of Tom Shannon as #VicePresident of Marketing for North America. With anticipated marketing approval, Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the US and Canada. Phillip Chan #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/g73bgJ5Q

Johnson & Johnson MedTech announced completion of the first cases in the clinical trial for the #OTTAVA™RoboticSurgicalSystem. The cases mark the first clinical experience with the #OTTAVASystem. Hani Abouhalka Peter Schulam, M.D., Ph.D. #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/gGhd9_Rc

AUROBINDO PHARMA LTD has received final US FDA approval to #manufacture and market Rivaroxaban Tablets USP, 2.5 mg, the generic equivalent of XARELTO (2.5 mg). The company plans to launch it in Q1 FY26. It also received tentative approval for 10 mg, 15 mg, and 20 mg strengths. #healthcare #PharmaIndustrialIndia Read More - https://lnkd.in/gza2Htep